These guidelines are under the continuing review of the Standing Advisory Committee for Tissues and Cellular Therapy Products (SACTCTP) and for Transfusion Transmitted Infection (SACTTI). This is t…
framework-organisation-chart.jpg (41KB)
lines-of-accountability.jpg (61KB)
Minutes of the JPAC meeting 16-03-2023.pdf (210KB)
18.5: References Metcalfe P, Watkins NA, Ouwehand WH, Kaplan C, Newman P, Kekomaki R, De Haas M, Aster R, Shibata Y, Smith J, Kiefel V, Santoso S. (2003). Nomenclature of Human P…
18.4: Patient testing 18.4.1: HPA typing Patients should be typed for HPA following the guidelines for donor HPA typing with the following exceptions: A p…
18.3: Donor testing 18.3.1: HPA typing Donors whose products may be used for fetal/neonatal transfusions should be HPA typed twice using samples collected on diff…
18.2: Methods 18.2.1: HPA typing methods HPA types should be determined using antibody-based and/or DNA/PCR-based techniques that have been validated in the laboratory.…
18.1: Reagent manufacture/reference preparations 18.1.1: HPA typing reagents There are several human platelet antigen (HPA) genotyping and phenotyping techniques. The <…
16.3: Terminology and nomenclature All HLA assignments, irrespective of the method, must comply with the latest report of the WHO Nomenclature Committee for Factors of the HLA System.
15.2: Clinical applications of blood group molecular typing Various clinical applications of blood group molecular typing are listed below: Fetal typing:1
14.1: Safety precautions All human cells should be treated as potentially infectious. Materials should be handled and discarded according to in-house documented procedures for potentiall…
13.5: Fetomaternal haemorrhage estimation by flow cytometry 13.5.1 Indications for testing For any D negative pregnant mother where the screening test indicates a fetomaternal…
13.6: Post-examination All patient records and test results should be maintained according to the requirements of the Caldicott Report (1997)8 and Data Protection…
13.4: Antibody quantification and titration Antibody quantification and titration is performed in RCI laboratories on patients’ samples, to support the prediction and management of HDFN …
13.3: Pre-transfusion testing 13.3.1: Resolution of anomalous grouping ABO grouping is the most important pre-transfusion serological test performed. Fully automated ABO and D…
13.2: Sample acceptance and labelling Visual inspection to determine the suitability for testing should consider the following in relation to the equipment, methods and samples used:…
13.1: Scope These specifications provide guidance on the tests required for investigations performed on patient samples in red cell immunohaematology (RCI) laboratories in UK Blood Trans…
5.12: Donor compensation The Blood Transfusion Services should have established procedures to ensure that any claim by a donor for compensation for any injury or loss allege…
5.11: Adverse events All adverse events must be documented and reported according to standard protocols. All bag/harness defects (e.g. pinhole leaks) must be recorded and all de…
5.9: Information to be provided to the donor post-donation The donor must be provided with information on care of the venepuncture site and requested to report any illness o…
5.8: Component donation by apheresis Guidance for collection procedures is identical to that for normal whole blood donations except for the points listed below.
5.7: Whole blood donation If necessary, the donor should be asked to open and close his/her hand slowly every 10–12 seconds to encourage a free flow of blood.
5.6: Performance of the venepuncture Venepuncture should only be undertaken by authorised and trained personnel. Items used for venepuncture must be st…